[{"id":"1a82176c-12db-4705-bb02-3bf4a332887d","acronym":"DELTA-2","url":"https://clinicaltrials.gov/study/NCT05393635","created_at":"2022-05-26T16:55:29.932Z","updated_at":"2024-07-02T16:35:58.890Z","phase":"Phase 1","brief_title":"ITIL-168 in Advanced Solid Tumors","source_id_and_acronym":"NCT05393635 - DELTA-2","lead_sponsor":"Instil Bio","biomarkers":" EGFR • ALK","pipe":"","alterations":" ","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • ITIL-168"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 12/08/2022","primary_completion_date":" 12/08/2022","study_txt":" Completion: 12/08/2022","study_completion_date":" 12/08/2022","last_update_posted":"2022-12-20"}]